Cargando…
Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
The incidence rate of pseudoprogression during immune checkpoint inhibitor monotherapy for non‐small cell lung cancer is reportedly 3.6%–6.9%, while pseudoprogression during chemoimmunotherapy is rare. Reports on pseudoprogression during dual immunotherapy combined with chemotherapy are lacking. Her...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011809/ https://www.ncbi.nlm.nih.gov/pubmed/36926450 http://dx.doi.org/10.1002/rcr2.1122 |